October 18, 2021
The U.S. FDA has approved Zimhi™ (naloxone HCl) 5mg/0.5mL, a high-dose naloxone injection, to treat opioid overdoses.
- Zimhi comes in a single-dose, prefilled syringe that can be used by individuals with or without medical It is currently the only FDA-approved 5mg dosage form of naloxone injection.
- Under the recommended dosing, one single-dose syringe should be injected into the thigh either intramuscularly (into the muscle) or subcutaneously (under the skin) as soon as possible in the event of a known or suspected opioid overdose. Emergency medical assistance should be sought immediately after delivery of the first dose.
- If the patient does not respond to treatment or relapses into respiratory depression, additional doses can be given every two to three minutes while waiting for emergency medical assistance.
- Manufacturer Adamis Pharmaceuticals plans to launch Zimhi in the first quarter of 2022.